The State of Ovarian Cancer: Exploring the Landscape of Systemic Therapy

Article

In this third webinar of our series, we will take an in-depth look at systemic therapy and how the landscape of treatment continues to evolve during this time. Join us on Wednesday, May 20, 2020 at 8 PM EST.

Date/Time: Wednesday, May 20, 2020 at 8 PM EST

In this third webinar of our series, we will take an in-depth look at systemic therapy and how the landscape of treatment continues to evolve during this time.

Click here to register today!

Topics:

  • Alternatives to intravenous therapy during the COVID-19 pandemic
  • Frontline therapy and frontline maintenance considerations
  • Second-line therapy and second-line maintenance considerations
  • Treatment in setting of platinum resistance

This OncLive® Weekly Webinar Series highlights best practices, treatment updates, and multidisciplinary approaches to ovarian cancer care through the COVID-19 pandemic.

Speakers:

Thomas J. Herzog, MD, Clinical Director University of Cincinnati Cancer Institute; Professor of Obstetrics and Gynecology, UC College of Medicine

Bradley Monk, MD, FACOG, FACS, Professor, Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital Phoenix, USA; Medical Director, US Oncology Research Network - Gynecologic Program; Co-director GOG-Partners; Member Board of Director GOG-Foundation

Professor of Gynecologic Oncology; Associate Director of Gynecologic Oncology, Levine Cancer Institute, Atrium Health

David M. O'Malley, MD, Professor; Director, Division of Gynecologic Oncology; Co-Director, Gyn Oncology Phase I Program, ORIEN Physician Liaison for OSUCCC-James, The Ohio State University and the James Cancer Center

Sponsored By:

Related Videos
Emil Lou, MD, PhD, FACP
Amma Asare, MD, PhD
Laura J. Chambers, DO
Casey M. Cosgrove, MD
Vaidehi Mujumdar, MD
Erin Crane, MD, MPH
Núria Agustí Garcia, MD
Yang Yang Hartwich, PhD
Gottfried Konecny, MD
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse